Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers.

RASSF/Hippo pathway colon cancers molecular biomarker

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
26 Nov 2021
Historique:
received: 19 10 2021
revised: 20 11 2021
accepted: 23 11 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 11 12 2021
Statut: epublish

Résumé

The aims of this study were to assess the frequency of promoter hypermethylation of the genes encoding the Ras associated domain family (RASSF)/Hippo pathway, as well as the impact on overall (OS) and progression-free survival (PFS) in a single-center retrospective cohort of 229 patients operated on for colon cancers. Hypermethylation status was investigated by methylation-specific PCR on the promoters of the

Identifiants

pubmed: 34885067
pii: cancers13235957
doi: 10.3390/cancers13235957
pmc: PMC8656858
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : APRI from the at the Caen University Hospital center
ID : grant number 2018

Références

Mol Carcinog. 2007 Oct;46(10):865-71
pubmed: 17538946
World J Gastroenterol. 2013 Jul 21;19(27):4363-73
pubmed: 23885148
Int J Oncol. 2014 Dec;45(6):2511-21
pubmed: 25270913
Exp Ther Med. 2012 Mar;3(3):391-396
pubmed: 22969901
Br J Cancer. 2019 Feb;120(4):387-397
pubmed: 30739911
Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8332-8344
pubmed: 31646563
Pathol Oncol Res. 2018 Apr;24(2):207-214
pubmed: 28434174
Biomed Pharmacother. 2017 Oct;94:774-780
pubmed: 28802229
Oncogene. 2009 Aug 20;28(33):2988-98
pubmed: 19525978
Oncol Lett. 2019 Oct;18(4):3994-4007
pubmed: 31565080
Curr Biol. 2015 Feb 2;25(3):296-305
pubmed: 25601544
Gastrointest Cancer Res. 2012 Jan;5(1):19-27
pubmed: 22574233
Biomed Res Int. 2013;2013:976765
pubmed: 23865079
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17
pubmed: 24639052
BMC Cancer. 2010 Oct 08;10:538
pubmed: 20932276
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6
pubmed: 10411935
Semin Cell Dev Biol. 2012 Sep;23(7):770-84
pubmed: 22898666
Biochem J. 2004 Jul 15;381(Pt 2):453-62
pubmed: 15109305
Mod Pathol. 2007 Mar;20(3):331-8
pubmed: 17277767
PLoS One. 2010 Jan 26;5(1):e8879
pubmed: 20126641
Gastroenterology. 2005 Jul;129(1):156-69
pubmed: 16012945
Oncogene. 2005 Jun 2;24(24):3987-94
pubmed: 15806169
Clin Cancer Res. 2005 Feb 15;11(4):1380-5
pubmed: 15746036
PLoS One. 2012;7(5):e36780
pubmed: 22615811
Cell Death Dis. 2019 Dec 5;10(12):928
pubmed: 31804463
Genes (Basel). 2016 May 18;7(5):
pubmed: 27213455
Nature. 2011 Jun 08;474(7350):179-83
pubmed: 21654799
Med Sci Monit. 2017 Nov 12;23:5389-5395
pubmed: 29128865
Pathology. 2019 Apr;51(3):261-267
pubmed: 30819540
J Mol Diagn. 2019 Jul;21(4):695-704
pubmed: 31055025
Eur J Surg Oncol. 2015 Mar;41(3):300-8
pubmed: 25468456
Clin Cancer Res. 2018 Mar 1;24(5):1062-1072
pubmed: 29180604
Cancer Res. 2002 Jul 1;62(13):3698-701
pubmed: 12097277
J Gastrointest Surg. 2016 Mar;20(3):648-55
pubmed: 26573851
Pathol Res Pract. 2020 Aug;216(8):153009
pubmed: 32703486
Biochem Biophys Res Commun. 2010 Jan 1;391(1):969-73
pubmed: 19962960
Clin Transl Oncol. 2016 Jun;18(6):608-16
pubmed: 26459248
Curr Treat Options Oncol. 2017 Apr;18(4):23
pubmed: 28391421
Oncol Lett. 2016 Sep;12(3):2194-2200
pubmed: 27602163
Int J Cancer. 2007 Jan 1;120(1):7-12
pubmed: 17013898
Oncotarget. 2017 Jul 22;8(35):58061-58071
pubmed: 28938537
Nat Genet. 2006 Jul;38(7):787-93
pubmed: 16804544
Cancer Res. 2016 Mar 15;76(6):1627-40
pubmed: 26759237
Br J Cancer. 2018 Oct;119(7):785-792
pubmed: 30287914

Auteurs

Marc Riffet (M)

Department of Pathology, CHU de Caen, 14000 Caen, France.
Normandie Université, UNICAEN, CEA, CNRS, ISTCT, CERVOxy Group, GIP CYCERON, 14074 Caen, France.

Yassine Eid (Y)

Polyclinique du Parc, 14000 Caen, France.
Normandie Université, UNICAEN, INSERM UMR 1086, ANTICIPE, 14000 Caen, France.

Maxime Faisant (M)

Department of Pathology, CHU de Caen, 14000 Caen, France.

Audrey Fohlen (A)

Normandie Université, UNICAEN, CEA, CNRS, ISTCT, CERVOxy Group, GIP CYCERON, 14074 Caen, France.
Department of Radiology, CHU de Caen, 14000 Caen, France.

Benjamin Menahem (B)

Normandie Université, UNICAEN, INSERM UMR 1086, ANTICIPE, 14000 Caen, France.
Department of Digestive Surgery, CHU de Caen, 14000 Caen, France.

Arnaud Alves (A)

Normandie Université, UNICAEN, INSERM UMR 1086, ANTICIPE, 14000 Caen, France.
Department of Digestive Surgery, CHU de Caen, 14000 Caen, France.

Fatéméh Dubois (F)

Department of Pathology, CHU de Caen, 14000 Caen, France.
Normandie Université, UNICAEN, CEA, CNRS, ISTCT, CERVOxy Group, GIP CYCERON, 14074 Caen, France.
Structure Fédérative D'oncogénétique cyto-MOléculaire du CHU de Caen (SF-MOCAE), CHU de Caen, 14000 Caen, France.

Guénaelle Levallet (G)

Department of Pathology, CHU de Caen, 14000 Caen, France.
Normandie Université, UNICAEN, CEA, CNRS, ISTCT, CERVOxy Group, GIP CYCERON, 14074 Caen, France.
Structure Fédérative D'oncogénétique cyto-MOléculaire du CHU de Caen (SF-MOCAE), CHU de Caen, 14000 Caen, France.

Céline Bazille (C)

Department of Pathology, CHU de Caen, 14000 Caen, France.
Normandie Université, UNICAEN, CEA, CNRS, ISTCT, CERVOxy Group, GIP CYCERON, 14074 Caen, France.

Classifications MeSH